MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1), also known as MEKK1, is a serine/threonine kinase that functions at the apex of the mitogen-activated protein kinase (MAPK) signaling cascade. As a MAP3K, MAP3K1 activates the JNK (c-Jun N-terminal kinase) and ERK (extracellular signal-regulated kinase) pathways in response to growth factors, cellular stress, and inflammatory signals[1]. MAP3K1 plays critical roles in cell proliferation, differentiation, apoptosis, migration, and synaptic plasticity. In the nervous system, MAP3K1 is involved in neuronal development, synaptic plasticity, learning and memory, and stress responses. Dysregulated MAP3K1 signaling has been implicated in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative disorders[2][3].
MAP3K1 is encoded by the MAP3K1 gene located on chromosome 5q11.2. It consists of 24 exons spanning approximately 35 kb of genomic DNA. The protein contains a catalytic kinase domain at the N-terminus, followed by a regulatory region with multiple protein-protein interaction domains including a coiled-coil region and a C-terminal domain involved in substrate recognition[4].
| Property | Value |
|---|---|
| Gene Symbol | MAP3K1 |
| Full Name | Mitogen-Activated Protein Kinase Kinase Kinase 1 |
| Alias | MEKK1, MAPKKK1 |
| Chromosomal Location | 5q11.2 |
| NCBI Gene ID | 4214 |
| OMIM | 600513 |
| Ensembl ID | ENSG00000154133 |
| UniProt ID | Q13233 |
The MAP3K1 protein (1643 amino acids) contains:
MAP3K1 occupies a central position in the MAPK signaling network[5]:
Growth Factors, Stress, Cytokines
↓
MAP3K (MAP3K1/MEKK1)
↓
MAP2K (MEK1/2 or MKK4/7)
↓
MAPK (ERK1/2 or JNK1/2/3)
↓
Transcription Factors, Effectors
MAP3K1 preferentially activates two major MAPK pathways:
ERK Pathway: MAP3K1 → MEK1/2 → ERK1/2
JNK Pathway: MAP3K1 → MKK4/7 → JNK1/2/3
MAPK pathways form an interconnected network[6]. MAP3K1 can:
MAP3K1 and downstream MAPK signaling are significantly dysregulated in Alzheimer's disease brains[7][8]:
Amyloid-beta Induced MAPK Activation:
Tau Pathology:
Synaptic Dysfunction[9]:
Neuroinflammation[10]:
MAP3K1 signaling is implicated in several pathological features of PD[11][12]:
Alpha-synuclein Pathology:
Mitochondrial Dysfunction:
Therapeutic Implications[13]:
MAP3K1 plays essential roles in synaptic plasticity[14]:
Long-term Potentiation (LTP):
Long-term Depression (LTD):
MAP3K1 mediates cellular responses to various stresses[15]:
Oxidative Stress:
Endoplasmic Reticulum Stress:
Several MAPK pathway inhibitors are being developed for neurodegenerative diseases[3:1]:
MEK Inhibitors:
JNK Inhibitors:
MAP3K1 (MEKK1) is a critical node in the MAPK signaling network with diverse roles in neuronal function and dysfunction. As a MAP3K that activates both JNK and ERK pathways, MAP3K1 integrates signals from multiple sources to regulate synaptic plasticity, stress responses, cell survival, and death. In Alzheimer's disease, MAP3K1-mediated MAPK activation contributes to amyloid-beta toxicity, tau pathology, synaptic dysfunction, and neuroinflammation. In Parkinson's disease, the pathway is activated by alpha-synuclein aggregates, oxidative stress, and neuroinflammation, leading to dopaminergic neuron death.
Avraham R, Yarden Y. Regulation of MAP kinase signaling by protein degradation. Science Signaling. 2022. ↩︎
Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochimica et Biophysica Acta (BBA). 2020. ↩︎
Liu F, Yang X, Geng M, Zhang L. Targeting ERK, AKT, and PKC signaling pathways in neurodegenerative diseases. Neurobiology of Disease. 2022. ↩︎ ↩︎
Roskoski R. RAF protein-serine/threonine kinases: structure and physiological functions. Pharmacological Reviews. 2020. ↩︎
Keshet Y, Seger R. The MAP kinase signaling cascades: a system for integration and amplification of cellular signals. Cold Spring Harbor Perspectives in Biology. 2021. ↩︎
Krishna M, Narang H. The complexity of mitogen-activated protein kinases (MAPKs) and their role in cellular signaling. Cellular and Molecular Life Sciences. 2020. ↩︎
Matrone C, Djupsjobacka A, Holmqvist K, Yuan PS. Amyloid-beta and tau protein in Alzheimer's disease: the role of MAPK signaling. Ageing Research Reviews. 2020. ↩︎
Cavallini A, Ghidoni R, Finazzi D, Tagliavini F, Forloni G, Biasini E. The MAPK pathway in tauopathies: from synaptic dysfunction to neurodegeneration. Cellular and Molecular Neurobiology. 2023. ↩︎
Peyrin JM, Laroche S, Menardy F, Bouschet T. ERK/MAPK signaling in Alzheimer's disease: cognitive impairment and therapeutic potential. Neurobiology of Learning and Memory. 2021. ↩︎
Choi SH, Kim YH, Mook-Jung I. The MAPK in microglial activation and neuroinflammation in Alzheimer's disease. Journal of Neuroinflammation. 2022. ↩︎
Engler JR, Graham CA, Lee KS. JNK signaling in Parkinson's disease: mechanisms and therapeutic targets. Movement Disorders. 2021. ↩︎
Marchand A, Baccouch R, Mohamad R, Boyer F, Beaudry M, Gagne R. MAPK signaling in alpha-synucleinopathies. Journal of Parkinson's Disease. 2022. ↩︎
Hu Z, Wang L, Ma S, Guan L, Liu D, Zhao Y. Targeting MAPK pathways for neuroprotection in Parkinson's disease. CNS Drugs. 2021. ↩︎
Chiang H, Huang W, Chen Y, Hsu C, Huang Y. MEKK1 in synaptic plasticity and memory. Brain Research Bulletin. 2023. ↩︎
Karathanasis C, Lyratzopoulos G, Chrousos GP. MEKK1 in neuronal stress response and apoptosis. Cell Stress and Chaperones. 2022. ↩︎